Bridging a gap: Surgical management of HIV-associated lipoatrophy

AIDS Reader

Volumn 14, Issue 9, 2004, Pages 472-475

  Moyle, Graeme J ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

HIV AIDS; Lipoatrophy; Polylactic acid; Surgery, cosmetic

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; COLLAGEN; DIDANOSINE; EMTRICITABINE; HYALURONIC ACID; HYDROXYAPATITE; LAMIVUDINE; POLITEF; POLY(METHYL METHACRYLATE); POLYACRYLAMIDE GEL; POLYLACTIC ACID; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SILICONE; TENOFOVIR; THYMIDINE DERIVATIVE;

ALLERGY; BIODEGRADABILITY; BODY FAT; CADAVER DONOR; CLINICAL TRIAL; CONFERENCE PAPER; DERMIS; DUAL ENERGY X RAY ABSORPTIOMETRY; ENDOPROSTHESIS; ESTHETIC SURGERY; FACE MALFORMATION; FASCIA; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMPLANT; INJECTION; LIPOATROPHY; PATIENT SATISFACTION; PLASTIC SURGERY; PROSTHESIS FAILURE; QUALITY OF LIFE; RHYTIDOPLASTY; RISK ASSESSMENT; SURGICAL TECHNIQUE; TREATMENT INDICATION; TREATMENT OUTCOME;

ABSORBABLE IMPLANTS; FACE; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; INJECTIONS; SURGERY, PLASTIC;

EID: 4544294877     PISSN: 10530894     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (17)

1. Collins E, Wagner C, Walmsley S. Psychosocial impact of the lipodystrophy syndrome in HIV infection. AIDS Reader. 2000;10:546-550.
2. Martin A, Smith DE, Carr A, et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS. 2004;18:1029-1036.
3. Hatano H, Miller KD, Yoder CP, et al. Metabolic and anthropometric consequences of interruption of highly active antiretroviral therapy. AIDS. 2000;14:1935-1942.
4. Moyle GJ, Lysakova L, Brown S, et al. A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection. HIV Med. 2004;5:82-87.
5. Lafaurie M, Dolivo M, Boulu D, et al. Treatment of facial lipoatrophy with injections of polylactic acid in HIV-infected patients. Presented at the 10th Conference on Retroviruses and Opportunistic Infections; February 10-14, 2003; Boston. Abstract 720.
6. Valantin MA, Aubron-Olivier C, Ghosn J, et al. Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA. AIDS. 2003;17:2471-2477.
7. Narins R, Brandt F, Leyden J, et al. A randomized, double-blind, multicenter comparison of the efficacy and tolerability of Restylane versus Zyplast for the correction of nasolabial folds. Dermatol Surg. 2003;29:588-595.
8. Ritt MJ, Hillebrand-Haverkort ME, ten Veen JH. Local treatment of facial lipodystrophy in patients receiving HIV protease inhibitor therapy. Acta Chir Plast. 2001;43:54-56.
9. Jones D. HIV facial lipoatrophy: etiology and methods of correction. In: Klein AW, ed. Tissue Augmentation in Clinical Practice: Procedures and Techniques. New York: Marcel Dekker; 2003.
10. Caye N, Le Fourn B, Pannier M. Surgical treatment of facial lipoatrophy [in French]. Ann Chir Plast Esthet. 2003;48:2-12.
11. Strauch B, Baum T, Robbins N. Treatment of human immunodeficiency virus-associated lipodystrophy with dermafat graft transfer to the malar area. Plast Reconstr Surg. 2004;113:363-370.
12. Talmor M, Hoffman LA, LaTrenta GS. Facial atrophy in HIV-related fat redistribution syndrome: anatomic evaluation and surgical reconstruction. Ann Plast Surg. 2002;49:11-17.
13. Orentreich D, Leone AS. A case of HIV-associated facial lipoatrophy treated with 1000-cs liquid injectable silicone. Dermatol Surg. 2004;30(4, pt 1):548-551.
14. Webster RC, Gaunt JM, Hamdan US, et al. Injectable silicone for facial soft-tissue augmentation. Arch Otolaryngol Head Neck Surg. 1986;112:290-296.
15. Brody H. Complications of expanded polytetrafluoroethylene (e-PTFE) facial implant. Dermatol Surg. 2001;27:792-794.
16. Oyafuso LK, Serra MS, Troppe BM. Polymethylmethacrylate (PMMA) for facial atrophy treatment: 5 years follow-up. Presented at the XV International AIDS Conference; July 11-16, 2004; Bangkok, Thailand. Abstract MoOrB1060.
17. Protopapa C, Sito G, Caporale D, Cammarota N. Bio-Alcamid in drug-induced lipodystrophy. J Cosmet Laser Ther. 2003;5:226-230.